Platelet LncRNA STARD4-AS1 and ELOA-AS1 quantitative detection method for non-small cell lung cancer diagnosis

The expression of STARD4-AS1 and ELOA-AS1 in platelets was detected by real-time fluorescence quantitative PCR, combined with the Logistic regression model, and solved the sensitivity and specificity of platelets in the diagnosis of non-small cell lung cancer, providing an efficient diagnostic kit, reducing diagnostic trauma.

CN119753143APending Publication Date: 2025-04-04THE PEOPLES HOSPITAL OF GUANGXI ZHUANG AUTONOMOUS REGION
0 Cites 0 Cited by

Patent Information

Application Number
CN202411946942.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-12-27
Publication Date
2025-04-04

AI Technical Summary

Technical Problem

The prior art lacks high sensitivity and specificity methods for detecting non-small cell lung cancer using platelets. Traditional diagnostic methods have problems with traumatic and tissue heterogeneity, and blood and fluid biopsy methods are not yet mature.

Method used

Real-time fluorescence quantitative PCR was used to detect the expression of long-chain non-coding RNAs STARD4-AS1 and ELOA-AS1 in platelets. The test was detected by designing specific primers, combined with the Logistic regression fitting data model for diagnosis, and non-small cell lung cancer diagnosis kit was provided.

Benefits of technology

It has achieved a high sensitivity and high specificity of non-small cell lung cancer diagnosis, reduced the traumaticity of the diagnosis, improved the diagnostic efficacy and sensitivity, and has clinical promotion value.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides a detection method for combining results of fluorescent quantitative PCR (polymerase chain reaction) of LncRNA (long non-coding ribonucleic acid) STARD4-AS1 and ELOA-AS1 of blood platelets for NSCLC (non-single-cell LC) diagnosis. The method sequentially comprises the following steps: 1) separating platelets and extracting RNA (Ribonucleic Acid); (2) synthesizing cDNA (complementary deoxyribonucleic acid); (3) screening of the LncRNA; (4) detecting the LncRNA through real-time fluorescent quantitative PCR (Polymerase Chain Reaction); 5) analyzing related results; and 6) establishing a Logistic regression fitting data model. The method is relatively high in sensitivity and specificity; the invention further provides a non-small cell lung cancer diagnostic kit which is high in cost performance and easy to popularize and apply.
Need to check novelty before this filing date? Find Prior Art